Concepedia

Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics

Chetan Lathia, John Lettieri, Frank Cihon, Martha Gallentine, Martin Radtke, P. R. Sundaresan

Cancer Chemotherapy and Pharmacology · 2005 · 208 citations · 10 references

DOI

Concepts

References

10

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Dirk Strumberg, Heike Richly, Ralf A. Hilger et al. · Journal of Clinical Oncology · 2004 · 871 citations · Full text

, , +16

THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE

Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf et al. · Drug Metabolism and Disposition · 2003 · 784 citations

, , +17

Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole

Klaus T. Olkkola, Janne T. Backman, Pertti J. Neuvonen · Clinical Pharmacology & Therapeutics · 1994 · 412 citations

, , +14

Inhibition of Cytochrome P-450 3A (CYP3A) in Human Intestinal and Liver Microsomes: Comparison of Ki Values and Impact of CYP3A5 Expression

Megan Gibbs, Kenneth E. Thummel, Danny D. Shen et al. · Drug Metabolism and Disposition · 1999 · 245 citations

, , +17

Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives

Wenjiang Zhang, Yamini Ramamoorthy, Tansel Kilicarslan et al. · Drug Metabolism and Disposition · 2002 · 245 citations

, , +17